Although MGMT promoter methylation has limited diagnostic value, it is of great importance to guide treatment decisions on the use of chemotherapy with alkylating agents for patients with IDH1-wild-type gliomas and GBMs (37). Here, IDH1 is linked to central nervous system cancer.